Antibody persistence 100 days following the second dose of BNT162b mRNA Covid19 vaccine in patients with chronic lymphocytic leukemia
Tamar Tadmor, Ohad Benjamini, Andrei Braester, Galia Rahav, Lior Rokach
Topics & Concepts
Chronic lymphocytic leukemiaPersistence (discontinuity)AntibodyLeukemiaImmunologyMedicineVirologyHematologyGeotechnical engineeringEngineeringSARS-CoV-2 and COVID-19 ResearchCAR-T cell therapy researchChronic Lymphocytic Leukemia Research